ESR1 and breast neoplasm: While estrogen receptor (ER)-negative breast tumors show substantial rates of pCR, complete response to NaCT in ER-positive breast tumors is limited.3 Patients with ER-positive breast cancer thus would benefit most from predictive markers that would allow enrichment of patients with potentially responsive disease and avoidance of ineffective treatment for others.